Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Lei Duan and Carl Maki.
Connection Strength

9.472
  1. Novel markers of MCL1 inhibitor sensitivity in triple-negative breast cancer cells. J Biol Chem. 2024 Jun; 300(6):107375.
    View in: PubMed
    Score: 0.840
  2. Determinants of Aurora kinase B inhibitor sensitivity in small cell lung cancer. Transl Lung Cancer Res. 2024 Feb 29; 13(2):223-228.
    View in: PubMed
    Score: 0.827
  3. Potential biomarkers for MCL1 inhibitor sensitivity. Cell Signal (Middlet). 2024; 2(1):144-147.
    View in: PubMed
    Score: 0.819
  4. CSE1L is a negative regulator of the RB-DREAM pathway in p53 wild-type NSCLC and can be targeted using an HDAC1/2 inhibitor. Sci Rep. 2023 09 27; 13(1):16271.
    View in: PubMed
    Score: 0.804
  5. Prolylcarboxypeptidase promotes IGF1R/HER3 signaling and is a potential target to improve endocrine therapy response in estrogen receptor positive breast cancer. Cancer Biol Ther. 2022 Dec 31; 23(1):1-10.
    View in: PubMed
    Score: 0.764
  6. Author Correction: RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC. Sci Rep. 2022 Mar 16; 12(1):4525.
    View in: PubMed
    Score: 0.723
  7. RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC. Sci Rep. 2022 01 20; 12(1):1049.
    View in: PubMed
    Score: 0.715
  8. Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells. J Mol Cell Biol. 2021 09 11; 13(6):433-444.
    View in: PubMed
    Score: 0.698
  9. JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells. Oncogene. 2019 07; 38(28):5643-5657.
    View in: PubMed
    Score: 0.590
  10. Alpha ketoglutarate levels, regulated by p53 and OGDH, determine autophagy and cell fate/apoptosis in response to Nutlin-3a. Cancer Biol Ther. 2019; 20(3):252-260.
    View in: PubMed
    Score: 0.569
  11. p53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a. J Mol Cell Biol. 2018 08 01; 10(4):331-340.
    View in: PubMed
    Score: 0.562
  12. The IGF-1R/AKT pathway determines cell fate in response to p53. Transl Cancer Res. 2016 Dec; 5(6):664-675.
    View in: PubMed
    Score: 0.501
  13. The prolyl peptidases PRCP/PREP regulate IRS-1 stability critical for rapamycin-induced feedback activation of PI3K and AKT. J Biol Chem. 2014 Aug 01; 289(31):21694-705.
    View in: PubMed
    Score: 0.422
  14. Erratum: P53-regulated autophagy and its impact on drug resistance and cell fate. Cancer Drug Resist. 2021; 4(4):903.
    View in: PubMed
    Score: 0.175
  15. P53-regulated autophagy and its impact on drug resistance and cell fate. Cancer Drug Resist. 2021; 4:85-95.
    View in: PubMed
    Score: 0.169
  16. Prolyl endopeptidase inhibitor Y-29794 blocks the IRS1-AKT-mTORC1 pathway and inhibits survival and in vivo tumor growth of triple-negative breast cancer. Cancer Biol Ther. 2020 11 01; 21(11):1033-1040.
    View in: PubMed
    Score: 0.164
  17. The IGF-1R/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis. Cancer Biol Ther. 2017 Nov 02; 18(11):895-903.
    View in: PubMed
    Score: 0.131
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.